- Home
- RERE vs NBTX Comparison
RERE vs NBTX Comparison
Compare RERE & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | NBTX |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 1.0B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RERE | NBTX |
|---|---|---|
| Price | $4.69 | $39.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.2M | 75.3K |
| Earning Date | 05-19-2026 | 03-31-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.70 | $58.17 |
| Revenue Next Year | $22.93 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $4.10 |
| 52 Week High | $6.47 | $57.14 |
Technical Indicators
Market Signals| Indicator | RERE | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 48.15 |
| Support Level | $4.27 | $38.89 |
| Resistance Level | $4.87 | $41.89 |
| Average True Range (ATR) | 0.29 | 3.32 |
| MACD | 0.01 | -1.31 |
| Stochastic Oscillator | 40.56 | 6.08 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.